[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sezary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sezary-syndrome":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,73,85,142,172,197,223,248,273,298,324,346,372],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054160","phase-1-durvalumab-with-or-without-lenalidomide-in-treating-patients-with-relapsed-or-refractory-cutaneous-or-peripheral-t-cell-lymphoma-100054160",false,"NCT03011814","Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma","A Phase 1\u002F2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed\u002F Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Registered into Revlimid REMS program\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =\\\u003C grade 1\n* Relapsed\u002Frefractory disease\n* Failed \\>= 2 prior systemic therapies \\*NOTE: For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin\n\nCUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY\n\n* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: \\>= stage IIB OR \\>= stage IB-IIA folliculotropic\u002Ftransformed MF; Phase 2: \\>= stage IB\n\n  * Stage of disease according to TNMB classification\n  * Pathology report must be diagnostic or be consistent with MF\u002FSS criteria\n  * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\n  * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used\n* Measurable disease per modified severity weighted assessment tool (mSWAT) and\u002For Sezary count\n* Baseline skin biopsy taken within 6 months available for central review submission\n\nPERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY\n\n* Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria\n* Measurable and\u002For evaluable disease per Lugano Classification\n* Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3\n\n  \\* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Platelets \\>= 100,000\u002Fmm\\^3\n\n  \\* Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total serum bilirubin =\\\u003C 2.2 mg\u002FdL\n* Aspartate aminotransferase (AST) =\\\u003C 2 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =\\\u003C 2 x ULN\n* Creatinine clearance of \\>= 60 mL\u002Fmin per the Cockcroft-Gault formula\n* If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin (PT) =\\\u003C 1.5 x ULN\n\n  \\* If on anticoagulant therapy: PT must be within therapeutic range of intended used of anticoagulants\n* Female of childbearing potential: negative urine or serum pregnancy test\n\n  \\* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female of child bearing potential: willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study medication\n\n  \\* Childbearing potential defined as not being surgically sterilized or have not been free from menses for \\> 1 year\n* Male: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy\n\nExclusion Criteria:\n\n* Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer vaccines\n* Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)\n* Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy\n* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy\n* Any skin-directed therapy within 14 days prior to initiating protocol therapy\n* Any radiation therapy within 21 days prior to initiating protocol therapy\n* Immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\n  * Systemic corticosteroids at physiologic doses of \\\u003C 10 mg\u002Fday of prednisone or equivalent\n* Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy\n* History of pneumonitis (non-infectious) that required steroids or current pneumonitis\n* Disease free of prior malignancies for \\>= 5 years with the exception of:\n\n  * Currently treated squamous cell and basal cell carcinoma of the skin\n  * Carcinoma in situ of the cervix, or\n  * Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision or\n  * Prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) that has\u002Fhave been surgically cured, or\n  * Any other malignancy that has\u002Fhave been curatively treated with surgery and\u002For localized radiation\n* Allergic reaction\u002F hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab\n* Female only: pregnant or lactating\n* Prior stem cell transplantation\n* Acute infection requiring systemic treatment\n* Known history of human immunodeficiency virus (HIV) infection\n* Active hepatitis B or C infection\n* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy\n* Current peripheral neuropathy \\>= grade 2\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment\n* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment; the following are exceptions to this criterion:\n\n  * Vitiligo or alopecia;\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or\n  * Psoriasis not requiring systemic treatment\n* History of primary immunodeficiency\n* Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide\n* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, social\u002Fpsychological issues, etc\n* In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","ALL","18 Years",{"count":19,"type":20},78,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This randomized phase I\u002FII trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.",[27,28,29,30,31,32,33,34],"Folliculotropic Mycosis Fungoides","Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides","Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Sezary Syndrome","Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2017-03-08",{"date":43,"type":20},"2030-04-14",{"name":45,"class":46},"City of Hope Medical Center","OTHER",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100382160","phase-2-mogamulizumab--low-dose-total-skin-electron-beam-tx-in-mycosis-fungoides--szary-syndrome-100382160","NCT04256018","Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome","A Phase 2 Single Center, Single Arm, Open Label Mogamulizumab Combined Upfront With Low Dose Total Skin Electron Beam Therapy (LD TSEBT) in Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS)","Inclusion Criteria:\n\n* Stages IB-IV MF or SS\n\n  1. Stages IB-IV MF or SS\n  2. At least 1 prior standard-of-care therapy\n  3. Prior LD-TSEBT (\\> 3 months prior) and prior mogamulizumab is allowed, as long as progressive disease (PD) did not occur while on therapy, and did not discontinue due to toxicities\n  4. ≥ 18 years of age\n  5. ECOG performance status of 0 to 2\n  6. All clinically-significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE, v 5.0).\n  7. MF and a known history of non-complicated staphylococcus colonization\u002Finfection is eligible provided that stable doses of prophylactic antibiotics continue.\n  8. The following minimum wash-out from previous treatments are required (prior to 1st day of treatment), if applicable.\n\n     • ≥ 2weeks for retinoids, interferons, Vorinostat, romidepsin, pralatrexate, or other systemic anti-cancer\u002FCTCL therapies\n\n     • ≥ 2 weeks for phototherapy, local radiation therapy\n\n     • ≥ 2 weeks for topical therapy (including topical steroid, retinoid, nitrogen mustard, or imiquimod)\n\n     • ≥ 12 weeks for total skin electron beam therapy\n\n     • \\> 12 weeks for alemtuzumab\n\n     • Rapidly progressive malignant disease may be enrolled prior to above periods after discussion with the Protocol Director.\n  9. Adequate hematologic function\n\n     • Absolute neutrophil count (ANC) ≥ 1,000 cells\u002FμL (≥ 1,000\u002Fmm3)\n\n     • Platelets ≥ 75,000 cells\u002FμL (≥ 75,000\u002Fmm3).\n  10. Adequate hepatic function\n\n      * Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN.\n      * Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN; or ≤ 5.0 x ULN in the presence of known hepatic involvement by CTCL.\n  11. Adequate renal function\n\n      • Calculated creatinine clearance ≥ 30 mL\u002Fmin using the Cockcroft-Gault formula.\n  12. If prior allogeneic hematopoietic stem cell transplant (HSCT), then must be free of graft-vs-host disease (GvHD) and receiving immunosuppressive therapy.\n  13. Women of childbearing potential (WOCBP) must have a negative pregnancy test.\n  14. WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.\n  15. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.\n\n      Exclusion Criteria:\n\n  \u003C!-- -->\n\n  1. MF with limited disease (Stage IA) or central nervous system (CNS) disease\n  2. Concomitant corticosteroid use. (with the exception that topical steroid and oral prednisone are allowed at ≤ 20 mg\u002Fday, if patient has been on a stable dose for at least 2 weeks prior to 1st day of treatment)\n  3. Pregnant or breastfeeding\n  4. Active autoimmune disease or history deemed by the investigator to be clinically significant\n  5. Known human immunodeficiency virus (HIV) positivity; or active hepatitis B or C.\n  6. Active herpes simplex or herpes zoster. Those receiving prophylaxis for herpes and who started taking medication at least 30 days prior to the Screening Visit, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study.",{"count":56,"type":20},30,[24],"The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF and SS.",[33,60],"Mycosis Fungoides",[62],"CTCL","2026-06-29",{"date":65,"type":39},"2026-07-01",{"date":67,"type":39},"2020-03-30",{"date":69,"type":20},"2026-12",{"name":71,"class":46},"Stanford University",1,{"id":74,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":25,"conditions":77,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":47},"100286681",{"count":19,"type":20},[23,24],[27,28,29,30,31,32,33,34],"2026-06-15",{"date":80,"type":39},"2026-06-16",{"date":41,"type":39},{"date":83,"type":20},"2026-08-30",{"name":45,"class":46},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":127,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100514411","a-registry-for-people-with-t-cell-lymphoma-100514411","NCT05978141","A Registry for People With T-cell Lymphoma","The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens","Inclusion Criteria:\n\n* Written informed consent\n* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.\n* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):\n\n  * T-cell prolymphocytic leukemia\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Aggressive NK-cell leukemia\n  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood\n  * Chronic active EBV infection of T- and NK-cell type, systemic form\n  * Hydroa vacciniforme-like lymphoproliferative disorder\n  * Adult T-cell leukemia\u002Flymphoma\n  * Extranodal NK\u002FT-cell lymphoma, nasal type\n  * Enteropathy-associated T-cell lymphoma\n  * Monomorphic epitheliotropic intestinal T-cell lymphoma\n  * Intestinal T-cell lymphoma, not otherwise specified (NOS)\n  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract\n  * Hepatosplenic T-cell lymphoma\n  * Subcutaneous panniculitis-like T-cell lymphoma\n  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)\n  * Sézary syndrome\n  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)\n  * Primary cutaneous Gamma-Delta T-cell lymphoma\n  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma\n  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)\n  * Peripheral T-cell lymphoma, not otherwise specified\n  * Angioimmunoblastic T-cell lymphoma\n  * Follicular T-cell lymphoma\n  * Nodal peripheral T-cell lymphoma with TFH phenotype\n  * Anaplastic large cell lymphoma, ALK-positive\n  * Anaplastic large cell lymphoma, ALK-negative\n  * Breast-implant associated anaplastic large cell lymphoma.\n* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.\n\nExclusion Criteria:\n\n* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and\u002For primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.\n* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.",{"count":93,"type":20},1000,"10 Years","OBSERVATIONAL","The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.",[98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,60,33,116,117,118,119,120,121,122,123,124,125,126],"T-cell Lymphoma","NK-Cell Lymphoma","T-cell Prolymphocytic Leukemia","T-cell Large Granular Lymphocytic Leukemia","Chronic Lymphoproliferative Disorder of NK Cells","Aggressive NK-cell Leukemia","Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)","Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood","Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form","Hydroa Vacciniforme-Like Lymphoproliferative Disorder","Adult T-cell Leukemia\u002FLymphoma","Extranodal NK\u002FT-cell Lymphoma, Nasal Type","Enteropathy-associated T-cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Intestinal T-Cell Lymphoma, Not Otherwise Specified","Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","Hepatosplenic T-cell Lymphoma","Subcutaneous Panniculitis-Like T-Cell Lymphoma","Primary Cutaneous Anaplastic Large Cell Lymphoma","Primary Cutaneous T-cell Lymphoma","Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Anaplastic Large Cell Lymphoma, ALK-Positive","Anaplastic Large Cell Lymphoma, ALK-negative","Breast Implant-Associated Anaplastic Large Cell Lymphoma",[128,129,130,131,132],"23-190","T-cell lymphoma","Memorial Sloan Kettering Cancer Center","T-cell Lymphoma Master Repository","TCLMR","2026-05-18",{"date":135,"type":39},"2026-05-20",{"date":137,"type":39},"2023-07-27",{"date":139,"type":20},"2030-07-27",{"name":130,"class":46},26,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100634132","phase-1-aclarubicin-plus-cyclophosphamide-vincristine-and-prednisone-caop-in-patients-with-previously-treated-cutaneous-t-cell-lymphoma-100634132","NCT07535710","Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma","A Multicenter, Open-Label, Phase 1\u002F2 Clinical Study of the Safety and Efficacy of Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form\n2. Age ≥ 60 years at enrollment\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n4. Histologically confirmed primary cutaneous T-cell lymphoma (CTCL) or Sézary syndrome (SS) (according to the fifth edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid System)\n5. Stage II-B, III, or IV (referring to the Olsen criteria of the International Society for Cancer Research (ISCL)\u002FUSCC\u002FEORTC, 2022)\n6. Patients who have failed at least one systemic therapy; psoralen combined with ultraviolet radiation therapy (PUVA) is not considered a systemic therapy\n7. All clinically significant toxicities caused by previous anticancer therapy have resolved to ≤ Grade 1 (according to NCI-CTCAE v5.0 criteria)\n8. Hematological, renal, and liver function tests meet the following requirements:\n\n   1. Absolute neutrophil count (ANC) ≥ 1,500 cells\u002FμL\n   2. Platelet count ≥ 100,000 cells\u002FμL\n   3. For patients with known bone marrow involvement, ANC ≥ 1,000 cells\u002FμL and platelets ≥ 75,000 cells\u002FμL\n   4. Total bilirubin ≤ 1.5 times the institutional upper limit of normal (ULN) (except for patients with Gilbert syndrome)\n   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known in C TCL, ≤ 5.0 × ULN\n   6. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance calculated by the Cockcroft-Gault formula \\> 50 mL\u002Fmin\n\nExclusion Criteria:\n\n1. Patients diagnosed with a malignancy within the past two years. Exclude the following situation: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA \\\u003C0.1 ng\u002FmL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal\u002Flobular carcinoma in situ diagnosed within the past two years, as long as there is no current evidence of active disease.\n2. Clinical evidence of central nervous system (CNS) infiltration.\n3. Large cell transformation (LCT). Patients with a history of LCT but no current invasive disease and no evidence of LCT on skin or lymph node pathology may be enrolled.\n4. Psychiatric illness, disability, or social circumstances that may affect the subject's safety, ability to provide informed consent, or poor compliance.\n5. Patients with significant uncontrolled comorbidities or infections, as follows:\n\n   1. Uncontrolled infection requiring intravenous antibiotics\n   2. Clinically significant heart disease (New York Heart Association class III or IV), unstable angina\n   3. History of angioplasty, stent implantation, or myocardial infarction within 6 months\n   4. Uncontrolled hypertension despite treatment with two antihypertensive medications (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg, measured on two consecutive occasions, one week apart)\n   5. Clinically significant arrhythmias\n   6. Uncontrolled diabetes mellitus\n6. Known or tested positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C.\n7. Active herpes simplex or herpes zoster. Patients who have started antiviral prophylaxis ≥30 days prior to the pretreatment visit, have no signs of active infection, and whose last active infection occurred more than 6 months ago may be enrolled and must continue taking prescribed medications during the study.\n8. Known active autoimmune disease (e.g., Graves' disease, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, psoriasis).\n9. Allergic reaction to study medications.\n10. History of allogeneic transplantation.\n11. Pregnancy (confirmed by β-hCG) or lactation.","60 Years",{"count":151,"type":20},37,[23,24],"Cutaneous T-cell lymphomas (CTCL) are a rare and heterogeneous group of extranidal T-cell lymphomas characterized by skin involvement. Current treatment options for CTCL are limited. Although responses have been demonstrated, their duration is often short, especially in patients with advanced stage disease. Additional treatment options are needed which demonstrate activity in cutaneous and extracutaneous sites. The traditional CHOP regimen (Cyclophosphamide, Hydroxydaunorubicin, Vincristine and Prednisone) has some efficacy for CTCL patients, but due to the cardiotoxicity of anthracyclines, patients can only receive a limited course of treatment. After stopping the regimen, most patients will experience relapse.\n\nAclarubicin, also known as aclacinomycin A, is an anthracycline type of antibiotic with significant anti-cancer properties. Previous studies have shown that aclarubicin only induces histone eviction without causing DNA damage, and it stands out in pre-clinical models and clinical studies, as it potently kills AML cells. Meanwhile, aclarubicin lacks cardiotoxicity, and can be safely administered even after the maximum cumulative dose of either doxorubicin or idarubicin has been reached. Aclarubicin's treatment indications include malignant lymphoma, but actual clinical application experience is limited.\n\nThe purpose of this study is to determine the maximum tolerated dose, safety and efficacy of aclarubicin combined with cyclophosphamide, vincristine, and prednisone (CAOP) for subjects with relapsed or refractory CTCL.",[155,156,33,157],"Cutaneous T-Cell Lymphoma Refractory","Cutaneous T-Cell Lymphoma, Relapsed","Cutaneous T Cell Lymphoma (CTCL)",[159,62,33,160],"Aclarubicin","systemic therapy","NOT_YET_RECRUITING","2026-04-14",{"date":164,"type":39},"2026-04-17",{"date":166,"type":20},"2026-03-30",{"date":168,"type":20},"2028-12-31",{"name":170,"class":46},"Shanghai Jiao Tong University School of Medicine",2,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},"100330869","phase-2-dosing-of-brentuximab-vedotin-for-mycosis-fungoides-sezary-syndrome-patients-100330869","NCT03587844","Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients","Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis","Inclusion Criteria:\n\nMycosis fungoides (MF) and Sezary Syndrome (SS)\n\n1. Pathologically confirmed mycosis fungoides\u002Fsezary syndrome at the enrolling institution, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher\n\n   ° CD30 negative mycosis fungoides patients are eligible.\n2. Age ≥ 18 years\n3. ECOG Performance Score ≤ 2\n4. For Cohort 1, patients who have not received brentuximab vedotin are eligible.\n5. For Cohort 2, patients who have previously had brentuximab vedotin for MF\u002FSS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2.\n6. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.\n\n   ° See section 6.2 Subject Exclusion Criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy.\n7. Topical or systemic steroids (equivalent to ≤ 10 mg\u002Fday of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and\u002For unnecessary suffering, after discussion with PI.\n8. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \\>200 within 7 days prior to C1D1.\n9. Females of childbearing potential must be on acceptable form of birth control per instutional standard.\n\nLymphomatoid papulosis (LyP)\n\n1. Pathologically confirmed lymphomatoid papulosis at the enrolling institution\n2. Requiring systemic treatment per investigator's discretion\n3. Age ≥ 18 years\n4. ECOG Performance Score ≤ 2\n5. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.\n6. Topical or systemic steroids (equivalent to ≤ 10 mg\u002Fday of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and\u002For unnecessary suffering.\n7. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count \\>200 within 7 days prior to C1D1.\n8. Females of childbearing potential must be on acceptable form of birth control per institutional standard\n\nExclusion Criteria:\n\n1. Concurrent use of other systemic anti-cancer agents or treatments for mycosis fungoides\u002Fsezary syndrome, or lymphomatoid papulosis.\n2. Grade 2 or greater neuropathy\n3. Severe renal impairment (CrCL \\\u003C30 mL\u002Fmin)\n4. Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C)\n\n   ° See Appendix E for Child Pugh Classification chart\n5. Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with treating provider.\n6. Previous use of brentuximab vedotin (for Cohort 1 ONLY)\n7. Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma).\n\n   * Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator.\n   * Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.\n8. For Cohort 2, patients who previously progressed on the standard 1.8mg\u002Fkg dose and schedule of brentuximab vedotin are ineligible.\n\n   * A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).",{"count":180,"type":20},58,[24],"The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.",[60,184,33],"Lymphomatoid Papulosis",[186,187],"Brentuximab Vedotin","18-147","2026-04-02",{"date":190,"type":39},"2026-04-03",{"date":192,"type":39},"2018-07-03",{"date":194,"type":20},"2027-07",{"name":130,"class":46},8,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100629676","lymphocyte-phenotype-of-autosomal-recessive-congenital-ichthyoses-mutated-nipal4-nipal4-nedd-100629676","NCT07477769","Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)","Phénotype Lymphocytaire Des Ichtyoses congénitales Autosomiques récessives mutées NIPAL4 (Nipal4-nEDD)","NIPALYMPHO","Inclusion Criteria:\n\n* Adult patients (\\> 18 years old)\n* ARCI-type ichthyosis with NIPAL4 mutation (Nipal4-nEDD)\n\nExclusion Criteria:\n\n* Ichthyosis that has not been genotyped or with mutations in different genes\n* Patients with concomitant inflammatory, infectious, or hematological conditions\n* Individuals subject to legal protection measures or deprived of their liberty by judicial or administrative decision\n* Individuals under guardianship\u002Fcuratorship\n* Opposition to the research",{"count":206,"type":20},10,"Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier. They manifest as abnormal desquamation (scaling) associated with varying degrees of inflammation (erythema). Around ten genes are currently implicated in ARCI. Nipal 4 is one of these genes, and mutations in it are found in around 1\u002F10 of genotyped ARCI patients.\n\nAs part of this follow-up, three Nipal4 ARCI (Nipal4-nEDD) patients followed by the dermatology department of Saint-Louis hospital (Paris) were diagnosed with Sezary syndrome, a rare and serious cutaneous lymphoma (incidence 1\u002F10,000,000), in adulthood (aged 30, 46, and 82). This lymphoma was diagnosed following a change in skin phenotype with worsening erythema, pruritus, and hyperkeratosis. The occurrence of two very rare diseases ( Nipal4-nEDD) and Sezary syndrome) in three patients raises the question of a non-coincidental association. The diagnosis of Sézary syndrome is based on a specific pathological circulating lymphocyte phenotype and is confirmed by skin histology. There is currently no obvious pathophysiological explanation for the concomitant occurrence of these two skin diseases. The blood lymphocyte phenotype of Nipal 4-nEDD patients without Sezary syndrome (SS) is unknown. A first step in investigating the mechanisms that could explain such an association would be to document this baseline lymphocyte phenotype in the Nipal 4-nEDD population without known SS.",[33,209],"Ichthyosis, Lamellar",[211,212,33,213],"nEDD","NIPA like domain containing4 protein, human","Lymphocyte Immunophenotyping","2026-03-12",{"date":216,"type":39},"2026-03-17",{"date":218,"type":20},"2026-04-01",{"date":220,"type":20},"2027-10-01",{"name":222,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":247},"100451367","extracorporeal-photopheresis-in-sezary-syndrome-100451367","NCT05157581","Extracorporeal Photopheresis in Sezary Syndrome","Open Label, Single-cohort, and Multi-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With Sézary Syndrome at Single-cell Resolution","ECP","Inclusion Criteria:\n\n1. Patient with an established diagnosis of Sezary syndrome (stage IVA1)\n2. Patients amenable for ECP\n3. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy\n4. Patients should have recovered from all adverse events related to prior therapy to ≤ grade 1\n5. Signed informed consent form prior to any protocol-specific procedures.\n\nExclusion Criteria:\n\n1. Visceral metastasis of lymphoma\n2. Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, or immunotherapy\n3. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection.\n4. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and\u002For comply with study protocol.\n5. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.\n6. Patients with known allergy to Methoxsalen or heparin (as part of SOC ECP procedure).\n7. Patients who are pregnant. -","100 Years",{"count":233,"type":20},20,"The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).",[33],[237],"extracorporeal photopheresis","2025-12-23",{"date":240,"type":39},"2025-12-30",{"date":242,"type":39},"2023-04-04",{"date":244,"type":20},"2028-12",{"name":246,"class":46},"Oleg E. Akilov, MD, PhD",3,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":72},"100071017","blood-urine-and-tissue-collection-for-cutaneous-lymphoma-eczema-and-atopic-dermatitis-research-100071017","NCT00177268","Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research","Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research","Inclusion Criteria:\n\n* 18 or older\n* able and willing to provide informed consent\n* diagnosed with CTCL\n* diagnosed with either atopic dermatitis or eczema\n\nExclusion Criteria:\n\n* Lack of CTCL, atopic dermatitis, or eczema diagnosis in medical record",{"count":256,"type":20},200,"This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.",[259,33,60,260,261],"Cutaneous T-cell Lymphoma","Eczema","Atopic Dermatitis",[259,33,60,263,264,265],"Blood\u002Ftissue banking","eczema","atopic dermatitis",{"date":240,"type":39},{"date":268,"type":39},"2004-10",{"date":270,"type":20},"2032-01",{"name":272,"class":46},"University of Pittsburgh",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":280,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":72},"100273556","tissue-repository-ctcl-collection-protocol-100273556","NCT02840747","Tissue Repository: CTCL Collection Protocol","A Tissue Repository for the Collection of Samples From Patients With Cutaneous T Cell Lymphoma and Healthy Volunteers","Inclusion Criteria:\n\n* Patients with CTCL or Lymphomatoid Papulosis (LYP): a clinical or histologic diagnosis of a) newly diagnosed, b) progressive, or c) relapsed CTCL or LYP who are initiating or changing therapy.\n* Patients with Sézary Syndrome (SS) or stage IV B CTCL as defined by blood involvement on flow cytometry or morphology: (1) ≥1000\u002FμL Sézary cells by morphology; (2) Cluster of differentiation 4 (CD4)\u002Fcluster of differentiation 8 (CD8) ratio ≥10; (3) CD4+cluster of differentiation 7 (CD7)- cells ≥40 percent; (4) or CD4+cluster of differentiation 26 (CD26)- cells ≥30 percent.\n* Ability to understand and willing to sign a willing informed consent document.\n* Age ≥ 18 years.\n\nInclusion Criteria for Age and Sex Matched Controls:\n\n* Matched for sex, and age +\u002F- 10 years.\n* Ability to sign informed consent document.\n* Patients with or without benign inflammatory skin conditions including, but not limited to, eczema, psoriasis, or dermatitis or Patients without skin conditions requiring treatment with systemic immunosuppressive, biologic, or chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Patients with a history of previous lymphoma other than CTCL or SS or LYP.\n* Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.\n* Current, viable pregnancy.\n* Anemia with a documented hemoglobin laboratory value of \\\u003C7.5 g\u002Fdl within the past 6 months.\n\nExclusion Criteria for Age and Sex Matched Controls:\n\n* Previous history of CTCL, SS, LYP, or any lymphoma.\n* Previous history of Human Immunodeficiency Virus (HIV) infection.\n* Anemia with a documented hemoglobin laboratory value of \\\u003C7.5 g\u002Fdl within the past 6 months.",true,{"count":282,"type":20},400,"This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples from patients with CTCL for future research studies. Collection and storage of tissue samples from control patients will also be carried out.",[285,184,286],"Lymphoma, T-Cell, Cutaneous","Sézary Syndrome",[184,286,288],"T-Cell Lymphoma","2025-11-03",{"date":291,"type":39},"2025-11-04",{"date":293,"type":4},"2016-07",{"date":295,"type":20},"2026-10",{"name":297,"class":46},"Columbia University",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":247},"100433940","phase-2-extracorporeal-photopheresis-and-mogamulizumab-for-the-treatment-of-erythrodermic-cutaneous-t-cell-lymphoma-100433940","NCT04930653","Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guideline\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age: \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) =\\\u003C 2\n* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS). Safety lead-in: \\>= stage IIB OR \\>= stage IB-IIA folliculotropic\u002Ftransformed MF. Phase 2: \\>= stage IB\n\n  * Stage of disease according to Tumor-Node-Metastasis-Blood (TNMB) classification\n  * Pathology report must be diagnostic or be consistent with MF\u002FSS criteria\n  * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\n  * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used.\n* Measurable disease per Modified Severity Weighted Assessment Tool (mSWAT) and\u002For Sezary count\n* Baseline skin biopsy taken within 6 months available for central review submission\n* Without bone marrow involvement: Absolute neutrophil count (ANC) \\>= 1,500\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: ANC \\>= 1,000\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Without bone marrow involvement: Platelets \\>= 100,000\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: Platelets \\>= 75,000\u002Fmm3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Creatinine clearance of \\>= 60 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease) (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =\\\u003C 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Hepatitis C virus (HCV)\\*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \\[RPR\\])\n\n  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Subjects with MF and a history of staphylococcus colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Prior mogamulizumab\n* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy\n* Any skin-directed therapy within 14 days prior to initiating protocol therapy\n* Any radiation therapy within 21 days prior to initiating protocol therapy\n* Immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\n  * Systemic corticosteroids at physiologic doses of \\\u003C 10 mg\u002Fday of prednisone or equivalent\n* Live, attenuated vaccine within 30 days prior to the first dose protocol therapy\n* Disease free of prior malignancies for \\>= 5 years with the exception of:\n\n  * Currently treated squamous cell and basal cell carcinoma of the skin, or\n  * Carcinoma in situ of the cervix, or\n  * Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision, or\n  * Prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) that has\u002Fhave been surgically cured, or\n  * Any other malignancy that has\u002Fhave been curatively treated with surgery and\u002For localized radiation\n* Active infection requiring antibiotics\n* Known hepatitis B or hepatitis C infection\n* Other active malignancy\n* Females only: Pregnant or breastfeeding\n* Prior stem cell transplantation\n* Acute infection requiring systemic treatment\n* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment\n* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:\n\n  * Vitiligo or alopecia\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or\n  * Psoriasis not requiring systemic treatment\n* History of primary immunodeficiency\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":306,"type":20},34,[24],"This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).",[27,310,33,311,312,313,314,315],"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Transformed Mycosis Fungoides","2025-10-10",{"date":318,"type":39},"2025-10-14",{"date":320,"type":39},"2022-10-19",{"date":322,"type":20},"2028-06-15",{"name":45,"class":46},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100609384","early-phase-1-a-phase-1-multicenter-open-label-prospective-first-in-human-dose-escalation-clinical-trial-of-domain-therapeutics-anti-ccr8-monoclonal-antibody-dt-7012-in-patients-with-relapsed-or-refractory-cutaneous-t-cell-lymphomas-ctcl-100609384","NCT07213882","A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)","CITY","Inclusion Criteria:\n\n1. Adult Patients (≥18 years) with no upper age limit\n2. Confirmed diagnosis of mycosis fungoides or Sezary syndrome\n3. Stage IB to IVB in the ISCL \u002F EORTC classification\n4. Relapsed or refractory (no response) after at least two systemic treatments\n5. ECOG performance status 0-1\n6. Adequate liver function:\n\n   * Total bilirubin ≤ 1.5 xULN, or Direct bilirubin ≤ 1.5xULN if total bilirubin is \\>1.5xULN, or total bilirubin \\>1.5 xULN if elevated total bilirubin is attributed to Gilbert's syndrome or to histologically-proven liver involvement by CTCL\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2,5 x ULN, unless elevated to up to 5 x ULN due to CTCL\n7. Adequate hematological function:\n\n   * Absolute neutrophil count of ≥ 1.5 G\u002FL without G-CSF support for at least 7 days\n   * Platelet count of ≥ 75 G\u002FL without platelet transfusion within 7 days\n   * Hemoglobin ≥ 9 g\u002FdL without RBC transfusion within 7 days\n8. Adequate renal function: creatinine clearance calculated by Cockcroft \\& Gault formula of ≥ 50 mL\u002Fmin\n9. HBV: negative blood HBs Ag or blood HBV DNA. Vaccinated patients may be included. Patients with HBc antibody may be included if HBV DNA is negative\n10. HCV: negative HCV serology, or negative HCV RNA if HCV serology is positive\n11. HIV: negative HIV serology\n12. Negative serum or urinary pregnancy test within 7 days or at baseline prior to study treatment in women of childbearing potential\n13. Patients must agree to use a highly effective contraceptive method from inclusion until:\n\n    * If the patient is a male: at least 6 months after the last dose of DT-7012. Men must refrain from donating sperm during this same period\n    * If patient is a female of childbearing potential: at least 6 months after the last dose of DT-7012\n14. Patients must have the following minimum wash-out from previous treatments:\n\n    * 12 weeks for total skin electron beam irradiation,\n    * 4 weeks for monoclonal antibodies\n    * 3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents\n    * 3 weeks for systemic retinoids, interferons, vorinostat, romidepsin, fusion proteins\n    * 3 weeks for phototherapy\n    * 2 weeks for topical therapy (including steroids, retinoids, nitrogen mustard or imiquimod). Topical steroids and oral steroids (10 mg prednisone equivalent\u002Fday maximum) are allowed, if the patient has been on a stable dose with stable symptoms for at least 4 weeks prior to study entry.\n15. Patient covered by any social security system (registered or being a beneficiary of such a scheme) for French participants only\n16. Signed informed consent\n\nExclusion Criteria:\n\n1. Known central nervous system involvement by CTCL\n2. Participation in any study of a health product within 30 days prior to study entry\n3. Patients with a history of other malignancies during the past three years (except for: non-melanoma skin cancer, lymphomatoid papulosis, curatively treated localized prostate cancer, curatively treated localized breast cancer, resected thyroid cancer, biopsy proven cervical intraepithelial neoplasia or cervical carcinoma in situ, which are not considered exclusion criteria).\n4. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), or angina, myocardial infarction, cerebrovascular accident, transient ischemic attack within 6 months prior to study entry\n5. Any severe acute or chronic medical or psychiatric condition\n6. Patients with immunodeficiency\n7. Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 1 week prior to first study drug dose\n8. Chronic use of systemic corticosteroids of prednisone or equivalent \\>10 mg prednisone equivalent\u002Fday for a chronic condition (washout of 8 days from start of treatment is accepted)\n9. Other immunosuppressive therapies are also excluded, (washout of 7 days from start of treatment is accepted)\n10. Autologous Hematopoietic Stem Cell Transplantation (HSCT) within 100 days prior to DT-7012 infusion\n11. Prior allogeneic HSCT\n12. Prior solid organ transplantation\n13. Patient with history of confirmed progressive multifocal leukoencephalopathy\n14. Known or suspected allergies, hypersensitivity, or intolerance to DT-7012 or its excipients\n15. Pregnant or breast-feeding woman, or desire (for both man and woman participant) to conceive a child within 6 months after end of treatment\n16. Patient under guardianship or curatorship and protected adults or unable to consent\n17. Coagulation disorder contra indicating intravenous infusion\n18. History of anaphylactic reaction following vaccination or immunotherapy\n19. History or current immune pneumonitis or interstitial lung disease",{"count":56,"type":20},[333],"EARLY_PHASE1","Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary involvement of the skin. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes. SS is defined as erythroderma (erythema of the entire skin surface), and circulating tumor blood cells. The circulating tumor T cells express CD4 and may lose expression of CD7 and CD26, while exhibiting in most cases aberrant expression of CD158k (KIR3DL2), which is a surface marker of Sézary cells. CCR8 is a surface marker of tumor-infiltrating regulatory T cells. It has recently be observed that CCR8 was expressed by tumor cells in CTCL and other peripheral T-cell lymphomas. CCR8 is expressed by skin resident-memory T cells which are believed to be the tumor cell-of-origin in mycosis fungoides. Domain Therapeutics (DT) showed the in vitro efficacy of their proprietary anti-CCR8 mAb DT7012 in the depletion of CTCL cells. Therapeutic depletion of CCR8-expressing cells by DT-7012 could eliminate tumor cells and activate the anti-tumor immunity in CTCL. We hypothesize that treatment with DT-7012 is effective in the treatment of relapsed or refractory (R\u002FR) CTCL as advanced MF and SS.",[157,60,33],[337,60,33],"Cutaneous T Cell Lymphoma","2025-10-02",{"date":340,"type":39},"2025-10-09",{"date":342,"type":20},"2026-01-01",{"date":344,"type":20},"2028-08-01",{"name":222,"class":46},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":352,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":371},"100603134","assessment-of-safety-and-efficacy-of-poteligeo-inj-20-mg-mogamulizumab-through-use-result-surveillance-100603134","NCT07132567","Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance","Inclusion Criteria:\n\n1. Adults 19 years of age or older\n2. Individuals who are confirmed to have received administration of the study drug for the purpose of \"the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies,\" or who are considered to require administration of the study drug in the investigator's opinion\n3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance\n\nExclusion Criteria\n\n1. Patients with hypersensitivity to any ingredients of this drug\n2. Patients who intend to use this drug for non-approved indications\n3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug","19 Years",{"count":354,"type":20},15,"The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.",[60,33],[358,359,360],"Poteligeo","mycosis fungoides","Sezary syndrome","2025-09-19",{"date":363,"type":39},"2025-09-22",{"date":365,"type":39},"2025-05-02",{"date":367,"type":20},"2028-11",{"name":369,"class":370},"Kyowa Kirin Co., Ltd.","INDUSTRY",6,{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":280,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":379,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":72},"100431902","predictive-and-prognostic-biomarkers-in-patients-with-mycosis-fungoides-and-szary-syndrome-100431902","NCT04904146","Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.","BIO-MUSE","Inclusion Criteria:\n\n* Age 18-100 years\n* Histologically confirmed (according to the World Health Organization (WHO)\u002FEORTC classification) MF\u002FSS stages I-IV\n* WHO performance status 0 -3\n* Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.\n* Written informed consent according to International Conference on Harmonization (ICH)\u002F(Good Clinical Practice (GCP), and Swedish regulations\n* No minimum or maximum required routine laboratory data\n\nExclusion Criteria:\n\nNot applicable. No exclusion criteria are specified.",{"count":380,"type":20},120,"A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.",[60,33],[384,385,360,386,387,388,389,390,391],"Skin lymphoma","Mycosis fungoides","Translational research","Biomarkers","Treatment prediction","Lymphoma microenvironment","Skin neoplasms","Treatment","2025-03-05",{"date":394,"type":39},"2025-03-10",{"date":396,"type":39},"2021-04-02",{"date":398,"type":20},"2027-04",{"name":400,"class":46},"Lund University Hospital"]